Selection from HEOR Bibliography

IMS logo
Search criteria
Condition: Pricing and reimbursement
 
Análisis de la implementación de los Informes de Posicionamiento Terapéutico en España
Authors: Míriam Solozabal, Laura Planellas, Elisabet Viayna, Neus Canal
Affiliations: Health Economics & Outcomes Research. Real-World Insights. IQVIA España
Publications: 
Revista Española de Economía de la Salud. 2019; 14(3):596-605
Document Types: , Article
Countries: , Spain
Abstract: https://www.economiadelasalud.com/Articulo.aspx?i=v14n3d018
Condition Year Language Analysis type
, Health policy, Pricing and reimbursement, Public Health 2019 Spanish , Clinical setting: hospital, Clinical setting: Primary care, Internet or Interactive voice response system, Pricing & Reimbursement, Public Health
 
 
WHAT INTERPRETATION OF ICERS IN ORPHAN DISEASES? A FRENCH EXAMPLE.
Authors: Moutier Hélène; Bourguignon Sandrine; Maurel Frédérique; Bodaghi Charles
Affiliations: RWI IQVIA France
Publications: 
ISPOR 2018
Document Types: , Poster
Countries: , France
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment, Health economics, Pricing and reimbursement, Rare Diseases 2018 English , Cost effectiveness, Pricing & Reimbursement, Willingness to pay
 
 
Overview of German AMNOG Dossiers with Price Analysis Before and After Early Benefit Assessment
Authors: Tremmel M, Batscheider A, Bocuk D, Roxlau T, Antoni B, Elena Mihaylova, Bonduelle D
Affiliations: IQVIA Commercial GmbH & Co. OHG, Munich, Germany IQVIA RDS Bulgaria EOOD, Sofia, Bulgaria
Publications: 
Document Types: , Abstract
Countries: 
Condition Year Language Analysis type
, Health economics, Health policy, Pricing and reimbursement 2018 English , Pricing & Reimbursement, Review
 
 
The Impact of Label Extensions on the Reimbursed Price of Pharmaceutical Products Assessed According to §35A SGB V in Germany Oncological and Metabolic Diseases
Authors: Schmalhofer C, Eheberg D, Tremmel M, Bocuk D, Roxlau T, Antoni B, Bonduelle D
Affiliations: IQVIA Commercial GmbH & Co. OHG, Munich, Germany
Publications: 
Document Types: , Abstract
Countries: , Germany
Condition Year Language Analysis type
, Health economics, Health policy, Metabolic Disorders , Oncology, Pricing and reimbursement 2018 English , Cost analysis, Pricing & Reimbursement
 
 
Healthcare Resource Utilization and Costs among Psoriasis Patients Treated with Biologics, Overall and by Disease Severity
Authors: Murage MJ, Anderson A, Oliveria SA, Casso D, Ojeh CK, Muram TM, Merola JF, Araujo AB
Affiliations: Murage MJ: Eli Lilly and Company; Anderson A: IQVIA; Oliveria SA: IQVIA; Casso D: IQVIA; Ojeh CK: Eli Lilly and Company; Muram TM: Eli Lilly and Company; Merola JF: Harvard Medical School; Araujo AB: Eli Lilly and Company
Publications: 
Journal of Medical Economics
Document Types: , Article
Countries: , USA
Abstract: https://doi.org/10.1080/13696998.2018.1472097
Condition Year Language Analysis type
, Dermatology, Patient Registries & Real-World Study Methods, Pricing and reimbursement 2018 English , Cost analysis, Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis
 
 
Valoración de la innovación, ¿es “el innovómetro” una herramienta útil y su clasificación reproducible?
Authors: Otermin A, Callejo D, Gasche D, Viayna E, Rubio M, Sumalla M, Solozabal M.
Affiliations: HEOR-RWI, IQVIA
Publications: 
XXXVIII Jornadas de Economía de la Salud, Gran Canaria 2018
Document Types: , Poster
Countries: , Spain
Abstract: http://www.aes.es/jornadas/es/
Condition Year Language Analysis type
, Health policy, Pricing and reimbursement 2018 Spanish , Pricing & Reimbursement
 
 
How a new innovation assessment tool relates to recent drug launches for Spanish National acess
Authors: Míriam Solozabal, Elisabet Viayna, Marta Rubio, Mireia Sumalla, Ane Otermin, David Gasche, Laura Planellas, Daniel Callejo
Affiliations: HEOR-RWI, IQVIA Spain
Publications: 
ISPOR Europe 2018. 10-14 November 2018 | Barcelona, Spain
Document Types: , Poster
Countries: , Spain
Abstract: https://www.iqvia.com/-/media/iqvia/pdfs/isporbarcelona2018posters/november-13/how-a-new-innovation-assessment-tool-relates-to-recent-drug-launches-for-spanish-national-access.pdf?la=en&hash=1D16D1D70ADE257D3A09480F1B1EEB002BDE83A4
Condition Year Language Analysis type
, Pricing and reimbursement 2018 English , Clinical setting: hospital, Pricing & Reimbursement
 
 
The impact of biosimilar launch on molecule price and pharmaceutical expense: the case of the insulin glargine in Italy
Authors: Tucci C1, Cioni L1, Mantuano M1, Tettamanti A1
Affiliations: 1 QuintilesIMS, Milan, Italy
Publications: 
ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland
Document Types: , Poster
Countries: , Italy
Condition Year Language Analysis type
, Diabetes, Health policy, Pricing and reimbursement, Regulatory 2017 English , Literature Review, Pricing & Reimbursement, Public Health
 
 
Drug commercialization before the pricing and reimbursement in Italy: the non negotiated C Class (C-nn)
Authors: Mantuano M1, Cioni L1
Affiliations: 1 QuintilesIMS, Milan, Italy
Publications: 
ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland
Document Types: , Poster
Countries: , Italy
Condition Year Language Analysis type
, Health policy, Pricing and reimbursement, Regulatory 2017 English , Literature Review, Pricing & Reimbursement, Public Health
 
 
Análisis de coste-efectividad de empagliflozina en pacientes con diabetes mellitus tipo 2 y enfermedad cardiovascular establecida en España [Analysis of cost-effectiveness of empagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease established in Spain].
Authors: Barrull C1, Massafrets M2, Planellas L1, Perulero N1
Affiliations: 1 RWI, QuintilesIMS, Barcelona 2 Market Access Department, Boehringer Ingelheim, Barcelona
Publications: 
XXXVII Jornadas de Economía de la Salud2017, 6 - 8 de septiembre, Barcelona, España
Document Types: , Poster
Countries: , Spain
Abstract: http://www.aes.es/jornadas/en/
Condition Year Language Analysis type
, Cardiovascular disease, Diabetes, Health economics, Pricing and reimbursement 2017 Spanish , Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Cost effectiveness, Cost utility, Literature Review, Patient questionnaire, Randomised controlled trial
 
 
Regional market access pathways for diagnostics in Italy.
Authors: Mantuano M1, Dionisi M2, Paolini D2, Gancitano G2, Urbinati D1
Affiliations: 1 IMS Health, Milan, Italy 2 Roche Diagnostics, Italy.
Publications: 
ISPOR 19th Annual European Congress, 2016, 29 October-2 November, Vienna, Austria.
Document Types: , Poster
Countries: , Italy
Condition Year Language Analysis type
, Health policy, Pricing and reimbursement, Regulatory 2016 English , Review
 
 
IMPACT OF POST-INSCRIPTION STUDIES ON REASSESSMENT IN FRANCE: A CASE STUDY ON ORPHAN DRUGS
Authors: Jubert H, Ouali I, Kolahi C
Affiliations: IMS Health France
Publications: 
19th ISPOR congress 2016
Document Types: , Abstract, Poster
Countries: , France
Abstract: https://www.ispor.org/research_pdfs/54/pdffiles/PHP311.pdf
Condition Year Language Analysis type
, Pricing and reimbursement 2016 English , Clinical setting: Primary care, Literature Review, Pricing & Reimbursement, Review
 
 
COSTS EVOLUTION OF CANCER THERAPIES IN EUROPE FROM 2004 TO 2014
Authors: Tetafort A, Aubert JM, Perrot D, Brigot G, Kolahi C, Ansolabehere X
Affiliations: IMS Health France
Publications: 
19th ISPOR Congress 2016
Document Types: , Abstract, Poster
Countries: , France, Germany, Italy, UK
Abstract: https://www.ispor.org/research_pdfs/54/pdffiles/PCN82.pdf
Condition Year Language Analysis type
, Oncology, Pricing and reimbursement 2016 English , Clinical setting: hospital, Cost analysis, Pricing & Reimbursement, Retrospective database analysis
 
 
Quantification of patient preference analysis_Wearing the federal joint committee lens to assess evidence
Authors: Gaba D1, Eheberg D, Bonduelle D
Affiliations: 1 Quintiles IMS, Gurgaon, India 2 QuintilesIMS, Munich, Germany
Publications: 
Document Types: , Poster
Countries: , Germany, India
Condition Year Language Analysis type
, Health status & patient reported outcomes, Pricing and reimbursement 2016 English , Pricing & Reimbursement
 
 
Best supportive care or therapy according to physicians choice as appropriate comparator for german HTA dossiers-an underestimated chance or risk for the benefit assessment
Authors: Bonduelle D1, Eheberg D1, Jakovac M1, Dannemann S1
Affiliations: 1 QuintilesIMS, Munich, Germany
Publications: 
Document Types: , Poster
Countries: , Germany
Condition Year Language Analysis type
, Pricing and reimbursement 2016 English , Pricing & Reimbursement
 
 
pCPA/CDR/pCODR Changes and Impact to Market Access in Canada
Authors: Millson B, Zhang Y
Affiliations: IMS Brogan, A unit of IMS Health, Kirkland, QC, Canada
Publications: 
2016 ISPOR Conference
Document Types: , Poster
Countries: , Canada
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/hta-ispor-poster-2016.pdf
Condition Year Language Analysis type
, Pricing and reimbursement 2016 English , Database Study
 
 
From centralized marketing authorization to national reimbursement - a challenging journey for new medical products with placebo controlled trials
Authors: Eheberg D1, Paulus G1, Dannemann S1, Batscheider A1
Affiliations: 1 IMS Health GmbH & Co. OHG, Munich, Germany
Publications: 
ISPOR 18th Annual European Congress, 7-11 November 2015, Milan, Italy
Document Types: , Poster
Countries: , Germany
Condition Year Language Analysis type
, Pricing and reimbursement 2015 English , Pricing & Reimbursement
 
 
DOES CONDITIONAL MARKETING AUTHORISATION INFLUENCE MARKET ACCESS IN FRANCE, ENGLAND, AND GERMANY?
Authors: Kaaniche A1, Troubat A1, Sherwood A2
Affiliations: 1IMS, PARIS, France, 2IMS Health, La Défense, France
Publications: 
ISPOR 18th Annual European Congress Milan, Italy November, 2015
Document Types: , Abstract, Poster
Countries: , France, Germany, UK
Condition Year Language Analysis type
, Health policy, Pricing and reimbursement 2015 English , Market impact
 
 
Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.
Authors: Detournay B1, Halimi S2, Robert J1, Deschaseaux C3, Dejager S4.
Affiliations: 1Cemka-Eval, Bourg-la Reine, France. 2Department of Diabetology, Endocrinology and Nutrition, Grenoble University Hospital Center, Grenoble, France ; University Joseph Fourier, Grenoble, France. 3Novartis Pharma SAS, Market Access Department, Rueil-Malmaison, France. 4Novartis Pharma SAS, Medical and Scientific Affairs, Rueil Malmaison, France ; Department of Diabetology, Metabolism and Endocrinology, Pitié-Salpétrière Hospital, Paris, France.
Publications: 
Vasc Health Risk Manag. 2015 Jul 17;11:417-25. doi: 10.2147/VHRM.S84507. eCollection 2015.
Document Types: , Article
Countries: , France
Condition Year Language Analysis type
, Diabetes, Pricing and reimbursement 2015 English , Prospective study, Retrospective database analysis
 
 
First experiences with the new testing examination and treatment methods in Germany: Is this a new AMNOG clone?
Authors: Bonduelle D1, Eheberg D1, Plantoer S1
Affiliations: 1 IMS Health, Munich, Germany
Publications: 
ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands
Document Types: , Poster
Countries: , Germany
Condition Year Language Analysis type
, Pricing and reimbursement 2014 English , Pricing & Reimbursement
 
 
Quality of life-a rarely acknowledged key category within the AMNOG process in Germany
Authors: Eheberg D., Shlaen R., Batscheider A., Gohlke A.
Affiliations: IMS Health, Munich, Germany
Publications: 
VALUE IN HEALTH 17 (2014) A323–A686
Document Types: , Abstract, Poster
Countries: , Germany
Condition Year Language Analysis type
, Pricing and reimbursement 2014 English , Quality of life
 
 
HTA, budget impact tools and international price referencing from China’s perspective: what are the current developments and future considerations?
Authors: Koh L1, Li SC2, Zhang M3, Glaetzer C1
Affiliations: 1 Johnson & Johnson, Singapore, Singapore 2 School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, Australia 3 IMS Consulting, Shanghai, China
Publications: 
ISPOR 6th Asia-Pacific Conference, Beijing, China, 6-9 September, 2014
Document Types: , Panel presentation
Countries: , China
Condition Year Language Analysis type
, Pricing and reimbursement 2014 English , Pricing & Reimbursement
 
 
Payment by use: Achieving a new value paradigm for oncology
Authors: Woolmore A, Simpson D
Affiliations: RWE Solutions, IMS Health, London, UK
Publications: 
AccessPoint, 2014, May; 4(8): 26-31
Document Types: , Article
Countries: 
Abstract: http://issuu.com/ims_heor_publications/docs/ims_rwe_accesspoint_8_-_250514f_iss
Condition Year Language Analysis type
, Oncology, Pricing and reimbursement 2014 English , Real World Evidence
 
 
High-value oncology targeted therapies: Opportunities and challenges in emerging Asia Pacific markets
Authors: Afable A, Caputo J
Affiliations: IMS Health, Asia-Pac, Singapore, Singapore
Publications: 
AccessPoint, 2014, May; 4(8): 46-50
Document Types: , Article
Countries: , Asia Pacific
Abstract: http://issuu.com/ims_heor_publications/docs/ims_rwe_accesspoint_8_-_250514f_iss
Condition Year Language Analysis type
, Oncology, Pricing and reimbursement 2014 English , Real World Evidence
 
 
Trends in time to market access in Europe - is it getting better?
Authors: Flostrand SJ1, Lor S1, Anon Y2
Affiliations: 1IMS Consulting Group, La Défense Cedex, France, 2IMS Health, La Défense Cedex, France
Publications: 
ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands
Document Types: , Poster
Countries: 
Condition Year Language Analysis type
, Health policy, Pricing and reimbursement 2014 English , Market impact
 
 
Reimbursement Patterns for Enbrel® (etanercept) As Senior Patients Transition From Private to Public Drug Plan Insurance
Authors: Garces K1 , Poulin-Costello M1, Millson B2
Affiliations: 1 Amgen Canada, Mississauga, ON, Canada 2 IMS Health Canada Inc, Kirkland, QC, Canada
Publications: 
CAPT 2014
Document Types: , Poster
Countries: , Canada
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/amgencapt-poster-print.pdf
Condition Year Language Analysis type
, Pricing and reimbursement 2014 English , Retrospective cohort analysis
 
 
Comparison of drug assessments in France, Germany and UK: is European HTA a reality?
Authors: Perrin l1, Troubat A1
Affiliations: 1. IMS Health, La Défense, France
Publications: 
ISPOR 16th Annual European Congress - Nov2013
Document Types: , Poster
Countries: , France, Germany, UK
Condition Year Language Analysis type
, Pricing and reimbursement 2013 English , Pricing & Reimbursement
 
 
A price comparison study of recent drugs in EU5, 2008-2012
Authors: 1. Le Pen C, 2. Vigier D, 2. Grandfils N
Affiliations: 1. Université Paris Dauphine, Paris France . 2. IMS Health, Paris La Défense France
Publications: 
16th annual European ISPOR
Document Types: , Abstract
Countries: , France
Condition Year Language Analysis type
, Pricing and reimbursement 2013 English , Pricing & Reimbursement
 
 
Impact de la baisse du taux de remboursement des anti-arthrosiques symptomatiques d’action lente (AASALs) sur la prescription des AINS par les médecins généralistes français
Authors: P Hilliquin (1); S Bouée (2); I Dardour (3); A Letierce (4); V Leblanc (3); - (1) Corbeil-Essonnes - France; (2) Bourg-la-Reine - France; (3) Courbevoie - France; (4) Boulogne-Billancourt - France
Affiliations: 
Publications: 
26ème congrès français de Rhumatologie
Document Types: , Poster
Countries: , France
Abstract: http://poster.rhumatologie.asso.fr/
Condition Year Language Analysis type
, Pain, Pricing and reimbursement, Rheumatology 2013 French , Retrospective database analysis
 
 
Accessibility of Orphan Drugs in France, United Kingdom and Germany: Different Approaches with Regard to HTA and Prices
Authors: N. Grandfils, H. Hounkanlin, A. Troubat
Affiliations: IMS Health, PARIS LA DEFENSE, France
Publications: 
ISPOR 16th - Dublin 02-03 Novembre 2013
Document Types: , Poster
Countries: , France, Germany, UK
Abstract: http://www.ispor.org/
Condition Year Language Analysis type
, Pricing and reimbursement 2013 English
 
 
A Cost-Utility Analysis of Ranibizumab in Age-Related Macular Degeneration Based on Real-Life Observational Data in France
Authors: De Pouvourville G1 ; Lafuma A2 ; Moeremans K3 ; Nivelle E3 ; Umuhire D4 ; Gerlier L3 ; Maurel F5 ; Ponthieux A6.
Affiliations: 1ESSEC Chair of Health Systems, Cergy, France ; 2Cemka Eval, Bourg La Reine, France ; 3IMS Health HEOR, Vilvoorde, Belgium ; 4IMS Health, Paris La Défense, France ; 5IMS Health, Paris La Défense, France ; 6Novartis Pharma S.A.S., Rueil-Malmaison Cedex, France.
Publications: 
ISPOR 16th - 02/03 novembre 2013 Dublin
Document Types: , Poster
Countries: , France
Abstract: www.ispor.org
Condition Year Language Analysis type
, Ophthalmology, Pricing and reimbursement 2013 English
 
 
Does Europe reward reformulations? A data driven analysis of value preservation through reformulation.
Authors: Hughes ALH1 ; Luft D1 ; Lions I2 ; Flostrand SJA3.
Affiliations: 1IMS Consulting Group, London, United Kingdom ; 2IMS Consulting Group, Basel, Switzerland ; 3IMS Consulting Group, Paris La Défense, France.
Publications: 
ISPOR 16th 02/06 Novembre Dublin
Document Types: , Poster
Countries: 
Abstract: www.ispor.org
Condition Year Language Analysis type
, Pricing and reimbursement 2013 English
 
 
Variability in hybrid drug availability and pricing in europe.
Authors: Flostrand SJA1, Lor S1, Hughes ALH2
Affiliations: 1IMS Consulting Group, La Défense, Paris, France, 2IMS Consulting Group, London, United Kingdom
Publications: 
ISPOR 16th 02/06 Novembre 2013 Dublin
Document Types: , Abstract
Countries: 
Abstract: www.ispor.org
Condition Year Language Analysis type
, Pricing and reimbursement 2013 English
 
 
The sharp decrease of drug's access to reimbursement in France in 2011
Authors: Hounkanlin H, Troubat A, Morlet-Vigier D
Affiliations: IMS Health, Puteaux, France
Publications: 
15th European ISPOR in 2012
Document Types: , Abstract, Poster
Countries: , France
Condition Year Language Analysis type
, Pricing and reimbursement 2012 English , Pricing & Reimbursement
 
 
Drug reimbursement maintenance : a French challenge in 2011
Authors: Hounkanlin H, Troubat A, Morlet-Vigier D
Affiliations: Ims health, Puteaux, France
Publications: 
15th European Ispor in 2012
Document Types: , Abstract, Poster
Countries: , France
Condition Year Language Analysis type
, Pricing and reimbursement 2012 English , Market impact
 
 
Impact of payer perceptions of pharma companies on access decisions - an analysis of unprompted expressions in payer interviews
Authors: Ruppert A, Petrie N, King Z, Plata A, Rao N
Affiliations: IMS Consulting Group, Cambridge, UK
Publications: 
ISPOR 15th Annual European Congress, 3-7 November 2012, Berlin, Germany
Document Types: , Poster
Countries: 
Abstract: http://www.ispor.org/congresses/Berlin1112/Posters1.aspx
Condition Year Language Analysis type
, Pricing and reimbursement 2012 English , Market impact
 
 
Indirect identification of payer perceptions through retrospective analysis of interview write-ups
Authors: Ruppert A, King Z, Petrie N, Rao N, Plata A
Affiliations: IMS Consulting Group, Cambridge, UK
Publications: 
ISPOR 15th Annual European Congress, 3-7 November 2012, Berlin, Germany
Document Types: , Poster
Countries: 
Abstract: http://www.ispor.org/congresses/Berlin1112/Posters4.aspx
Condition Year Language Analysis type
, Pricing and reimbursement 2012 English , Pricing & Reimbursement
 
 
Real World Evidence: Meeting the challenge of stakeholder needs for demonstrating value in Asia
Authors: Nelson M1, Ngorsuraches S2, Caputo J3
Affiliations: 1 IMS Health, Alexandria, US 2 Prince of Songkla University, Songkla, Thailand 3 IMS Health, Singapore
Publications: 
ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan, September 2nd – 4th 2012
Document Types: , Podium presentation
Countries: , Asia Pacific
Condition Year Language Analysis type
, Pricing and reimbursement 2012 English , Pricing & Reimbursement
 
 
Issues in adapting Global Health Economic Models to Emerging Markets: A conversation with Health Authorities, Pharmaceutical Industry and Consultants in Asia Pacific
Authors: Arnold RJG1, Xuan J2, Hu S3, Lee KKC4
Affiliations: 1 HEOR, IMS Health, New York, NY, USA 2 Pfizer, New York, NY, USA 3 Shanghai Bureau of Health, Fudan University, Shanghai, China 4 Monash University Sunway Campus, Bandar Sunway, Malaysia
Publications: 
ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan, September 2nd – 4th 2012
Document Types: , Workshop
Countries: 
Abstract: http://www.ispor.org/conferences/Taipei0912/workshops.asp
Condition Year Language Analysis type
, Pricing and reimbursement 2012 English , Workshop
 
 
Conducting Real-World Studies in emerging Asian markets
Authors: Lara N1, Caputo J2, Lai H-J3, Yin-Yin Huang G4
Affiliations: 1 IMS Health, Barcelona, Spain 2 IMS Health, Singapore, Singapore 3 Merck, Sharp & Dohme Corp., Taipei, Taiwan 4 IMS Health, Taipei, Taiwan
Publications: 
ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan, September 2nd – 4th 2012
Document Types: , Workshop
Countries: , Asia Pacific
Abstract: http://www.ispor.org/conferences/Taipei0912/workshops.asp
Condition Year Language Analysis type
, Pricing and reimbursement 2012 English , Workshop
 
 
Cost-Effectiveness Modeling in Cancer
Authors: Lamotte M1, Vandekerckhove S1
Affiliations: 1IMS Health, Brussels
Publications: 
AccessPoint, Nov 2012; Vol 3(5); 26- 29
Document Types: , Article
Countries: 
Abstract: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Services/Pharma%20Commercial%20Effectiveness/Health%20Economics%20_%20Outcomes%20Research/AccessPoint-5-281012%20F.pdf
Condition Year Language Analysis type
, Pricing and reimbursement 2012 English , Cost effectiveness
 
 
Cost-effectiveness of Tapentadol prolonged-release (PR) compared to oxycodone controlled release (CR) in patients with chronic severe non-cancer pain in Ireland
Authors: Obradovic M.1, Ikenberg R.2, Hertel N.3, Liedgens H.1
Affiliations: 1 Grünenthal GmbH, Aachen, Germany, 2 IMS Consulting Group, Nuremberg, Germany, 3 IMS Consulting Group, London, UK
Publications: 
ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain
Document Types: , Poster
Countries: , Ireland
Condition Year Language Analysis type
, Pricing and reimbursement 2011 English , Cost effectiveness
 
 
Indications using real-world data in United States commercially-insured population
Authors: Schabert V1, Gandra SR2, Watson C2, Fox KM3, Yeaw J4, Goodman S4, Milev S5, Harrison DJ2
Affiliations: 1IMS Health, Falls Church, VA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 4IMS Health, Watertown, MA, USA, 5IMS Brogan, A unit of IMS, Ottawa, ON, Canada
Publications: 
ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain
Document Types: , Poster
Countries: , USA
Condition Year Language Analysis type
, Pricing and reimbursement 2011 English , Economic evaluation
 
 
Market access barriers for Biosimilars in Spain and Germany: Epoetin Alfa Example
Authors: Hurtado P, Vieta A, Espinós B, Badia X
Affiliations: IMS Health, Barcelona, Spain
Publications: 
ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain
Document Types: , Poster
Countries: , Germany, Spain
Condition Year Language Analysis type
, Pricing and reimbursement 2011 English , Market impact
 
 
Modeling cost-effectiveness of drug treatments for severe chronic non-cancer pain in Portugal
Authors: Obradovic M.1, Ikenberg R.2, Hertel N.3, Gouveia M.4, Liedgens H.1
Affiliations: 1 Grünenthal GmbH, Aachen, Germany, 2 IMS Consulting Group, Nuremberg, Germany, 3 IMS Consulting Group, London, UK, 4 Católica School of Business and Economics, Lisbon, Portugal
Publications: 
ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain
Document Types: , Poster
Countries: , Portugal
Condition Year Language Analysis type
, Pricing and reimbursement 2011 English , Cost effectiveness
 
 
Optimizing strategic direction with systematic value development.
Authors: Joy K1, Lewis SJ2
Affiliations: 1 Health Economics and Outcomes Research, IMS Health, Falls Church, VA, USA 2 BCBS of Colorado/Nevada, Lafayette, CO, USA
Publications: 
ISPOR 15th Annual International Meeting, May 15-19, 2010, Atlanta, GA, USA
Document Types: , Workshop
Countries: 
Abstract: http://www.ispor.org/meetings/atlanta0510/Workshops.asp#sessionI
Condition Year Language Analysis type
, Pricing and reimbursement 2010 English ,
 
 
Developing global road maps for reimbursement processes used in health technology assessment: pharmaceuticals, medical devices, and diagnostics.
Authors: Sullivan N1, Szeinbach S2, Seoane-Vazquez E2, Matuszewski K3, Mayo K4, Holmstrom S5, Wilson G6, Chicoye A7
Affiliations: 1Technology Assessment Evaluation Group, LLC, Encinitas, CA, USA, 2Ohio State University, Columbus, OH, USA, 3Elsevier/Gold Standard, Tampa, FL, USA, 4Bridgehead International Consulting, Denville, NJ, USA, 5Astellas Pharma Europe, Leiderdorp, The Netherlands, 6GE Healthcare, Buckinghamshire, UK, 7IMS HEALTH, PUTEAUX CEDEX, France
Publications: 
ISPOR 15th Annual International Meeting, May 15-19, 2010, Atlanta, GA, USA
Document Types: , Poster
Countries: 
Abstract: http://www.ispor.org/meetings/atlanta0510/Posters2.aspx
Condition Year Language Analysis type
, Pricing and reimbursement 2010 English ,
 
 
Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions.
Authors: Hess G, Nordyke RJ, Hill J, Hulnick S.
Affiliations: 1IMS Health (formally SDI Health), Plymouth Meeting, Pennsylvania, 2Leonard Davis Institute, University of Pennsylvania, Pennsylvania, 3Amgen Inc, Thousand Oaks, California
Publications: 
Am J Hematol. 2010 Nov;85(11):838-43.
Document Types: , Article
Countries: 
Abstract: http://www.ncbi.nlm.nih.gov/pubmed?term=effects of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions&cmd=correctspelling
Condition Year Language Analysis type
, Pricing and reimbursement 2010 English
 
 
Desigualdades en la financiación de medicamentos entre comunidades autónomas en España [Inequalities in the financing of medicines among autonomous regions in Spain]
Authors: Vieta A, Badia X
Affiliations: Vieta A1, Badia X1 1Health Economics and Outcomes Research, IMS Health, Barcelona, Spain,
Publications: 
Medicina Clínica (Barc). 2009;132(9):364-368
Document Types: , Article
Countries: , Spain
Condition Year Language Analysis type
, Pricing and reimbursement 2009 Spanish
 
 
Complex Attention-Deficit/Hyperactivity Disorder: Patient Characteristics, Health Care Utilization And Costs In A Retrospective Observational Claims Study
Authors: Hess G1, Sasane R2, Hill J1, Hodgkins P2, Shah MR1
Affiliations: 1IMS Health, former SDI Health, Plymouth Meeting, PA, USA, 2Shire Pharmaceuticals, Wayne, PA, USA
Publications: 
Value in Health Volume 12, Issue 7 , Page A361, October 2009
Document Types: , Article
Countries: 
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(10)74773-2
Condition Year Language Analysis type
, Health economics, Pediatrics, Pricing and reimbursement 2009 English , Cost analysis, Cost utility, Observational study
 
 
Freie Arzneimittelpreise in Deutschland – eine Fiktion? Auswirkungen der Methode des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) zur Kosten-Nutzen-Bewertung auf die Preisbildung von Arzneimitteln [Free pricing for pharmaceuticals in Germany - a fiction? Effects of the method of the institute for quality and economic efficiency in health care for cost-utility-evaluation regarding the pricing of pharmaceuticals]
Authors: Pirk O1, Fricke F-U1
Affiliations: 1 IMS Health, Nuremberg, Germany
Publications: 
Pharm. Ind. 70(4): 452–456
Document Types: , Article
Countries: , Germany
Condition Year Language Analysis type
, Pricing and reimbursement 2008 German , Pricing & Reimbursement
 
 
The comparison of different modelling techniques in cost effectiveness analysis: Using stroke care as an example.
Authors: Saka O1, Samyshkin Y3, McGuire A2, Wolfe CCDA1
Affiliations: 1 Division of Health and Social Care Research, King’s College, London, UK 2 London School of Economics and Political Science, LSE Health and Social Care, London, UK 3 IMS Health, London, UK.
Publications: 
7th European Conference on Health Economics Rome (Italy), 23-26 July 2008 - Faculty of Economics, University of Rome.
Document Types: , Conference
Countries: , UK
Condition Year Language Analysis type
, Pricing and reimbursement 2008 English , Cost effectiveness
 
 
Developing key performance indicators for the Australian reimbursement system
Authors: Abela M, Davey P, Carroll J, Brown B, Yates R
Affiliations: 
Publications: 
ISPOR 10th Annual Meeting
Document Types: , Poster
Countries: , Australia
Condition Year Language Analysis type
, Pricing and reimbursement 2008 English , Pricing & Reimbursement
 
 
Preisbildung und Erstattung [Pricing and reimbursement]
Authors: Pirk O
Affiliations: IMS Health, Nuremberg, Germany
Publications: 
Schöffski O, Fricke F-U, Guminski W (ed.). Pharmabetriebslehre, Berlin-Heidelberg, Springer, 2008, 155-172
Document Types: , Book chapter
Countries: 
Condition Year Language Analysis type
, Pricing and reimbursement 2008 German , Methodology
 
 
More Policy Initiatives in the Australian National Reimbursement System That Will Reduce Costs Dramatically
Authors: Davey PJ, Abela MJ and Aristides M.
Affiliations: 
Publications: 
ISPOR Ninth Annual International Meeting, Arlington, VA. May 16-19, 2004.
Document Types: , Poster
Countries: , Australia
Condition Year Language Analysis type
, Pricing and reimbursement 2007 English
 
 
Inequalities in the financing of drugs among autonomous regions in Spain
Authors: Badia X1, Vieta A1
Affiliations: 1Health Economics and Outcomes Research, IMS Health, Barcelona, Spain,
Publications: 
ISPOR 11th Annual European Congress 2008 November 8-11, Athens, Greece
Document Types: , Poster
Countries: , Spain
Condition Year Language Analysis type
, Pricing and reimbursement 2007 English
 
 
Outcomes Research and Pharmaceutical Pricing.
Authors: Tierce JC.
Affiliations: 
Publications: 
42nd Annual DIA Meeting, Philadelphia, PA, June 2006.
Document Types: , Abstract
Countries: 
Condition Year Language Analysis type
, Pricing and reimbursement 2006 English
 
 
Medicare Part D Reimbursement Hotlines: Just What the Doctor Ordered.
Authors: Braun L, DeKoven MP, De Masi C, Maltz J, Ross H.
Affiliations: 
Publications: 
Product Management Today. 2006 September; 17(9): 34-36, 38-39
Document Types: , Manuscript in preparation
Countries: , USA
Condition Year Language Analysis type
, Pricing and reimbursement 2006 English
 
 
Ensuring Access for Specialty Pharmaceuticals through Payer Education.
Authors: Dekoven MP, Marlo K, Robinson S.
Affiliations: 
Publications: 
Specialty Pharma. 2006 Jan/Feb; 2(1): 62-65.
Document Types: , Manuscript in preparation
Countries: , USA
Condition Year Language Analysis type
, Pricing and reimbursement 2006 English
 
 
Impact of an inspector's stamp approval policy into the atypical antipsychotic market in andalusia (Spain)
Authors: Badia X, Vieta A, Lara N, Giménez E
Affiliations: 
Publications: 
ISPOR 2007 10th Annual European Congress
Document Types: , Abstract
Countries: , Spain
Condition Year Language Analysis type
, Pricing and reimbursement 2006 English
 
 
Pricing reimbursement and health outcomes
Authors: Davey P
Affiliations: 
Publications: 
Regional Conference in Cost-effective Healthcare 2006
Document Types: , Invited speaker
Countries: 
Condition Year Language Analysis type
, Pricing and reimbursement 2006 English , Pricing & Reimbursement
 
 
Copyright 2024 IMS Health Incorporated. All rights reserved.